A shadow hangs over the race against Ebola as scientists battle a deadly outbreak without a viable virus sample.
Global researchers are forced to rely on decades-old historical strains to test experimental vaccines for the current crisis.
The rare Bundibugyo strain has already sickened over 1,100 people across the Democratic Republic of the Congo and Uganda.
Nearly 280 lives have been lost while the lack of fresh isolates compromises critical laboratory test validation.
Deepening political rifts over pathogen ownership and strict border controls stifle the international transit of these infectious materials.
Developing nations increasingly resist sharing biological data without explicit guarantees of affordable medical access for their own citizens.
This sovereignty dispute mirrors a broader global deadlock at the World Health Organization over fair benefit-sharing frameworks.
Congo officials maintain that no formal requests for physical virus samples have been received by the government.
The critical research delay persists even as a humanitarian doctor recently brought the infection home to France.
Experts warn that analyzing genetic sequences alone cannot match the certainty of testing an authentic, living viral isolate.